SOURCE: Agennix AG

Agennix AG

June 22, 2011 04:11 ET

Agennix Hires Jill Porter as Senior Vice President of Pharmaceutical Development

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - Jun 22, 2011) - Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced the appointment of Jill Porter, Ph.D. as Senior Vice President, Pharmaceutical Development, reporting to Dr. Rajesh Malik, Chief Medical Officer. In this position, Dr. Porter is leading all activities related to supply chain, global production and CMC (chemistry, manufacturing and controls) for talactoferrin, an oral immunotherapy being studied for the treatment of non-small cell lung cancer and for severe sepsis.

Rajesh Malik, M.D., Chief Medical Officer, said, "I am very pleased to welcome Dr. Porter to Agennix. She has extensive experience in leading production and supply chain activities and developing strategic plans in these areas for both development-stage and marketed biologic products. Dr. Porter is an excellent addition to our management team in an area of critical importance, as we prepare for a possible regulatory filing for talactoferrin and a potential commercial launch."

Dr. Porter has nearly twenty years of biopharmaceutical industry experience. She has held senior executive positions with responsibility for manufacturing and process development at Taligen Therapeutics, Altus Pharmaceuticals and Alexion Pharmaceuticals, where she worked immediately prior to joining Agennix. She worked for many years in positions of increasing responsibility at Hoffman-La Roche, including leading the Biopharmaceuticals department, with responsibility for the clinical and commercial manufacturing of two biologic drugs. Dr. Porter has experience in clinical and commercial supply chain management, as well as with regulatory filings and product approvals. She received a Ph.D. in agricultural engineering from Purdue University and an MBA from Columbia University.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company's most advanced program is talactoferrin, an oral immunotherapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer and in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix is also continuing the development of this program for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. There can be no guarantee that the Company will move talactoferrin forward in development for severe sepsis in a timely manner, if at all. Even if the results from our later stage trials with talactoferrin, including the ongoing FORTIS-M trial in non-small cell lung cancer, are considered positive, they may not be sufficient to gain marketing approval in the United States or any other country, and the regulatory authorities may require additional information, data and/or further pre-clinical or clinical studies to support approval. In such event, there can be no guarantee that the Company will have or be able to obtain the financial resources to conduct any such additional studies or that such studies will yield results sufficient for approval. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Agennix™ is a trademark of the Agennix group.

Contact Information

  • For further information, please contact:
    Barbara Mueller
    Manager, Investor Relations & Corporate Communications
    Phone: +49 (0)89 8565 2693
    ir@agennix.com

    In the U.S.:
    Laurie Doyle
    Senior Director, Investor Relations & Corporate Communications
    Phone: +1 609 524 5884
    laurie.doyle@agennix.com

    Additional media contact for Europe:
    MC Services AG
    Raimund Gabriel
    Phone: +49 (0) 89 210 228 0
    raimund.gabriel@mc-services.eu

    Additional investor contact for Europe:
    Trout International LLC
    Lauren Williams
    Vice President
    Phone: +44 207 936 9325
    lwilliams@troutgroup.com